 |
 |
No that one is stem cell, this one is a growth factor using a virus-guided delivery to the region. The general view is that a disease-modifying treatment will be in this form (Growth Factor) before stem cells. considering the lengthy time it takes for the beaureacracy of bringing a drug/solution to fruition, it will be years before treatment is avail to the public. We need the Apple's developers to work in medical research. In a way, it is our demand for absolute proof for safety of use, and our ready-to-sue-the drug company that make a quick time-to-market cycle not possible imho. getting desperate with this darn disease. willing to sign any consent form now :-) ----- Original Message ----- From: "Steve Rack" <[log in to unmask]> To: <[log in to unmask]> Sent: Thursday, April 29, 2010 11:07 PM Subject: Re: Ceregene has Initiated a New Phase 1/2 Trial Of CERE-120 for Parkinso n 's Disease > Is this the Dennis Turner who went ahead with Dr. Levesque and injected > stem cells into his brain? > > >>from: PR Newswire press release >>April 28, 2010, 7:00 a.m. EDT · >>Ceregene has Initiated a New Phase 1/2 Trial Of CERE-120 for Parkinson's >>Disease"SAN DIEGO, April 28, 2010 /PRNewswire via COMTEX/ -- >>Ceregene, Inc., a biopharmaceutical company, announced today that >>enrollment is proceeding in a new Phase 1/2 clinical study evaluating >>CERE-120, a gene therapy product which delivers the neurotrophic factor >>neurturin, to dying neurons in Parkinson's disease patients. This new >>clinical study follows a completed Phase 2 trial and builds on experience >>gained in that trial, by enhancing the dosing regimen and optimizing the >>duration of patient follow up. >>The new study was initiated in the fourth quarter of 2009 and is >>proceeding as planned. The ongoing Phase 1/2 trial will enroll six >>patients with advanced Parkinson's disease. The first four patients have >>been treated safely and two additional patients will be treated over the >>next two months. This Phase 1 open label portion of the trial is being >>conducted by Drs. Mark Stacy and Dennis Turner at Duke University School >>of Medicine, Drs. Michele Tagliati and Ron Alterman at Mount Sinai Medical >>Center, New York, and Drs. Stewart Factor and Nicholas Boulis at Emory >>University Hospital. Ceregene expects to initiate the next phase of this >>trial (a sham-surgery-controlled, double-blind Phase 2 portion) beginning >>during the third quarter of this year. The Phase 2 portion will include 10 >>leading US neurological medical centers. " >>full article >>at:http://www.marketwatch.com/story/ceregene-has-initiated-a-new-phase-12-trial-of-cere-120-for-parkinsons-disease-2010-04-28?reflink=MW_news_stmp >> >> >> >>__._,_.___ >> >>__,_._,___ >> >>---------------------------------------------------------------------- >>To sign-off Parkinsn send a message to: >>mailto:[log in to unmask] >>In the body of the message put: signoff parkinsn > > > -- > Steve in VT > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: > mailto:[log in to unmask] > In the body of the message put: signoff parkinsn > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn